Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway

International Journal of Molecular Medicine

Volumn 27, Issue 4, 2011, Pages 607-615

  Fan, Yuqi ^a   Meng, Shu ^a   Wang, Yue ^a   Cao, Jiatian ^a   Wang, Changqian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atherosclerosis; Cell signaling; Inflammation; Visfatin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CD147 ANTIGEN; DAPORINAD; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PYRROLIDINE DITHIOCARBAMATE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR RELA;

ANTIGEN EXPRESSION; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTIGENS, CD147; CELL LINE; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; RECEPTOR, INSULIN; RETINOID X RECEPTORS; SIGNAL TRANSDUCTION;

EID: 79952209017     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.621     Document Type: Article

References (34)

1. Fukuhara A, Matsuda M, Nishizawa M, et al: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005. (Pubitemid 40139988)
2. Chen MP, Chung FM, Chang DM, et al: Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299, 2006.
3. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD and Elisaf MS: Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30: 323-326, 2007. (Pubitemid 47008083)
4. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y and Inukai T: Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56: 451-458, 2007. (Pubitemid 46427838)
5. Yilmaz MI, Saglam M, Carrero JJ, et al: Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 23: 241-248, 2009.
6. Kai H, Ikeda H, Yasukawa H, et al: Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32: 368-372, 1998. (Pubitemid 28396484)
7. Schmidt R, Bultmann A, Ungerer M, et al: Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113: 834-841, 2006.
8. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476, 1999. (Pubitemid 30005109)
9. Ohki R, Yamamoto K, Mano H, Lee RT, Ikeda U and Shimada K: Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J Hypertens 20: 685-691, 2002. (Pubitemid 34913712)
10. Romacho T, Azcutia V, Vazquez-Bella M, et al: Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 51: 2455-2463, 2009.
11. Revollo JR, Korner A, Mills KF, et al: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375, 2007. (Pubitemid 350011996)
12. Formentini L, Moroni F and Chiarugi A: Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 77: 1612-1620, 2009.
13. Billington RA, Genazzani AA, Travelli C and Condorelli F: NAD depletion by FK866 induces autophagy. Autophagy 4: 385-387, 2008. (Pubitemid 351458108)
14. Van der Veer E, Ho C, O'Neil C, et al: Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 282: 10841-10845, 2007. (Pubitemid 47100731)
15. Hasmann M and Schemainda I: FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442, 2003. (Pubitemid 37413486)
16. Dahl TB, Yndestad A, Skjelland M, et al: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115: 972-980, 2007. (Pubitemid 46328290)
17. Major TC, Liang L, Lu X, Rosebury W and Bocan TM: Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 22: 1200-1207, 2002. (Pubitemid 34764874)
18. Vaddi K, Nicolini FA, Mehta P and Mehta JL: Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation 90: 694-699, 1994. (Pubitemid 24242734)
19. Woo CH, Lim JH and Kim JH: Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 173: 6973-6980, 2004.
20. Rocha VZ and Libby P: Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6: 399-409, 2009.
21. Cheng KH, Chu CS, Lee KT, et al: Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32: 268-274, 2008.
22. Adya R, Tan BK, Chen J and Randeva HS: Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31: 758-760, 2008.
23. Adya R, Tan BK, Chen J and Randeva HS: Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205: 113-119, 2009.
24. Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78: 356-365, 2008. (Pubitemid 351556097)
25. Liu SW, Qiao SB, Yuan JS and Liu DQ: Visfatin stimulates production of monocyte chemotactic protein-1 and interleukin-6 in human vein umbilical endothelial cells. Horm Metab Res 41: 281-286, 2009.
26. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B and Pestell RG: NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12: 73-90, 2001. (Pubitemid 32294588)
27. Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370-380, 2009.
28. Xie H, Tang SY, Luo XH, et al: Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210, 2007. (Pubitemid 46411878)
29. Mayi TH, Duhem C, Copin C, et al: Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages. FEBS J 277: 3308-3320, 2010.
30. Fukuhara A, Matsuda M, Nishizawa M, et al: Retraction. Science 318: 565, 2007.
31. Kim SR, Bae YH, Bae SK, et al: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783: 886-895, 2008.
32. Li Y, Zhang Y, Dorweiler B, et al: Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283: 34833-34843, 2008.
33. Razny U, Wator L, Polus A, et al: Hepatocyte RXR alpha deletion in mice leads to inhibition of angiogenesis. Genes Nutr 4: 69-72, 2009.
34. Na SY, Kim HJ, Lee SK, et al: IkappaBbeta interacts with the retinoid X receptor and inhibits retinoid-dependent transactivation in lipopolysaccharide- treated cells. J Biol Chem 273: 3212-3215, 1998.